We bring our expertise in discovery and development of gene expression signatures to customized partnerships with biopharmaceutical and diagnostics companies.

GenomicsNext™ Research Studies

We offer our GenomicsNext platform for performing liquid biopsy testing in discovery and development of gene expression readouts combined with DNA variants determination to highly enhance your genomics research.

• Perform essential alteration testing
• Identify tissue expression biomarkers in liquid
• Develop de novo expression signatures for new clinical research programs
• Add an extra dimension of gene expression exploration to your genomic mutation studies
• Enrich trials with high-resolution expression-based stratification
• Amplify your biomarker discovery through adding gene expression to ctDNA

Biopharma & Diagnostics Partners

While DNA alteration-based tissue biomarkers have long had a clear path to liquid biopsy, expression-based targets like those used in antibody-drug conjugates (ADCs) have remained confined to tissue testing.

GeneCentric’s GenomicsNext platform changes that. By inferring gene expression directly from ctDNA, we enable the development of liquid biopsy versions of tissue-based expression tests – opening the door to novel CDx strategies, faster trial enrollment, and greater access to patients.

Biopharmaceutical and diagnostics partners can leverage the novel, multimodal clinical-genomic data generated by the GenomicsNext platform. Contact us to find out how to gain access to our proprietary database and tools to unlock real-world data exploration and discovery.

Learn More